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Children with Wiskott–Aldrich syndrome (WAS) are often first diagnosed with immune
thrombocytopenia (ITP), potentially leading to both inappropriate treatment and the delay
of life-saving definitive therapy. WAS is traditionally differentiated from ITP based on the
small size of WAS platelets. In practice, microthrombocytopenia is often not present or not
appreciated in children with WAS. To develop an alternative method of differentiating WAS
from ITP, we retrospectively reviewed all complete blood counts and measurements of
immature platelet fraction (IPF) in 18 subjects with WAS and 38 subjects with a diagnosis
of ITP treated at our hospital. Examination of peripheral blood smears revealed a wide
range of platelet sizes in subjects withWAS. Mean platelet volume (MPV) was not reported
in 26% of subjects, and subjects in whom MPV was not reported had lower platelet
counts than did subjects in whom MPV was reported. Subjects with WAS had a lower
IPF than would be expected for their level of thrombocytopenia, and the IPF in subjects
with WAS was significantly lower than in subjects with a diagnosis of ITP. Using logistic
regression, we developed and validated a rule based on platelet count and IPF that was
more sensitive for the diagnosis of WAS than was the MPV, and was applicable regardless
of the level of platelets or the availability of the MPV. Our observations demonstrate that
MPV is often not available in severely thrombocytopenic subjects, which may hinder the
diagnosis of WAS. In addition, subjects with WAS have a low IPF, which is consistent with
the notion that a platelet production defect contributes to the thrombocytopenia of WAS.
Knowledge of this detail of WAS pathophysiology allows to differentiate WAS from ITP
with increased sensitivity, thereby allowing a physician to spare children with WAS from
inappropriate treatment, and make definitive therapy available in a timely manner.
Keywords: thrombocytopenia, differential diagnosis, immature platelet fraction, Wiskott–Aldrich syndrome,
immune thrombocytopenic purpura
Introduction
Immune thrombocytopenia (ITP) is the most common cause of newly discovered isolated throm-
bocytopenia in childhood (1), with an incidence of 1.9–6.4 in 100,000 children per year, and
a prevalence of 9.3 in 100,000 boys (2). ITP is also a diagnosis of exclusion (3). Therefore, in
order to diagnose the most common cause of newly recognized thrombocytopenia in children,
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all less common causes must first be ruled out. This leads to
a situation wherein the need for parsimonious use of diagnos-
tic resources conflicts with the imperative to make a diagnosis
by ruling out other diagnoses, potentially leading to premature
closure in the diagnosis of boys newly found to be thrombocy-
topenic. Premature closure, a known source of diagnostic error
(4), can lead to two potential adverse consequences – treatment
for a disease that is felt to be present but, in fact, is not, and
delay of diagnosis and treatment of the disease that is actually
present. Extensive resources have been invested by the American
Society of Hematology in developing guidelines to diagnose ITP
expeditiously, attempting to minimize both misdiagnosis of less
common forms of thrombocytopenia and potentially costly, low-
yield, and/or invasive investigations (3).
Another cause of newly recognized thrombocytopenia in boys,
from which ITP must be differentiated, is Wiskott–Aldrich syn-
drome (WAS). WAS is an X-linked genetic disease, of widely
varying clinical severity, which includes aspects of immunod-
eficiency, autoimmunity, and cancer predisposition in addition
to microthrombocytopenia. The timely diagnosis of WAS, par-
ticularly its distinction from ITP, is important for a number
of reasons. Immunosuppression is a first-line treatment for ITP
(3). This treatment carries an increased risk in immunodefi-
cient patients with WAS. Failure to diagnose WAS can lead to
the delay of appropriate treatment. With respect to definitive
treatment, hematopoietic cell transplant (HCT) for WAS has
been felt to be most efficacious in younger children (5–7). Sim-
ilarly, gene therapy for WAS is suspected to be most effica-
cious in very young children (8) as is the case for a number
of other primary immunodeficiencies (9–11). Failure to diag-
nose WAS in a patient with newly recognized thrombocytopenia
can lead to mistakes of omission and commission that may be
fatal.
Classically, WAS is distinguished from other forms of newly
recognized thrombocytopenia by virtue of small platelet size (1,
2, 12). This is traditionally recognized on review of a periph-
eral blood smear, a key part of the evaluation of suspected ITP
(3). Alternatively, modern hematology analyzers report the mean
platelet volume (MPV) numerically.
Nevertheless, it is not always the case that patients with WAS
have small platelets. Cases of WAS have been described with
normal (13, 14) or even increased (15)MPV. Furthermore, platelet
size in one WAS patient was reported to vary over time with the
dose of immunoglobulin replacement (16).
Another problematic aspect of using MPV in the differen-
tial diagnosis of newly recognized thrombocytopenia is that the
parameter is often difficult to measure in moderate to severe
thrombocytopenia (17), which is precisely the clinical situation in
which the differential diagnosis is most important.
In our own cohort of patients with WAS, data on date of onset
of symptoms and date of diagnosis are available for 21 patients
with no family history of WAS. For these patients, the average
diagnostic delay was 5 years (median 1.5 years, range 9 days to
27 years). Alternative laboratory investigations that could suggest
the diagnosis of WAS and lead to molecular testing in an accept-
able minority of cases of newly recognized thrombocytopenia
would be useful.
The number of platelet parameters available from modern
hematology analyzers is greater than it has been in the past
(17, 18). One parameter that is now commonly reported is the
immature platelet fraction (IPF) (19–21). Immature platelets, like
reticulocytes, are recognized by the persistence of RNA leading to
reticulation on analysis (19, 21–23). As with the reticulocyte index
in anemia, the IPF is thought to increase in thrombocytopenic
states due to peripheral destruction of platelets and to be inap-
propriately normal in thrombocytopenia with impaired platelet
production (23).
Wiskott–Aldrich syndrome has classically been described as a
disease of platelet destruction similar to ITP (24). Nevertheless,
data in patients with WAS and in Wiskott–Aldrich syndrome
protein (WASp) knockout mice suggest that there is a component
of decreased platelet production in the thrombocytopenia ofWAS
(25, 26). On this basis, we hypothesized that the IPF might be
a useful parameter to add to the platelet count and MPV in the
clinically important differential diagnosis of WAS and ITP. As a
preliminary step in exploring this hypothesis, we retrospectively
analyzed hematologic data collected in the course of routine care
of patients with either WAS or ITP at the Clinical Center of the
National Institutes of Health (CC NIH) in Bethesda, MD, USA.
By combining the measure of IPF with the platelet count, we
derived a rule to suggest when it might be appropriate to consider
a diagnosis of WAS. When evaluated for a subsequent cohort of
subjects, this rule showed appropriate diagnostic characteristics
to be used as an inexpensive screening test for WAS.
Materials and Methods
The use of diagnoses and platelet, MPV, and IPF values
of subjects with ITP and WAS was exempted from IRB
review by the hospital’s Office of Human Subjects Research
(certificates BTRIS_2013_615_SOKOLIC_R_NHGRI and
BTRIS_2014_711_SOKOLIC_R_NHGRI). Consent to use these
data was obtained from the principal investigators of the protocols
upon which the specimens were drawn.
Immature platelet fraction became a clinically reportable
parameter at the CC NIH in May of 2009. All measures of platelet
counts, MPVs, and IPF reported at the hospital fromMay of 2009
through March 26, 2013 in subjects with a discharge diagnosis of
either WAS or ITP were collected using the Biomedical Transla-
tional Research Information System (BTRIS). Data were collected
stripped of personal identifiers. The blood for these assays had
initially been collected in the course of routine or investigational
evaluation on protocols approved by the various institutional
review boards of the NIH intramural research program.
Unique subject identifiers created by BTRIS were attached to
each record and used to associate diagnoses with laboratory values
for each blood draw. The frequency of absent data for MPV
was calculated, as were average platelet counts for blood draws
including and not includingMPV. Single blood draws fromwhich
platelet count, MPV, and IPF were all reported, were selected for
further analysis. Two strategies were used to prevent subjects with
more frequent measurements from influencing the analysis more
than did subjects with few or single measurements. One strategy
was to average multiple values from single subjects. The other was
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to use only the first-blood draw for each subject. We refer to the
data obtained using the first strategy as the per-subject average
data set for the derivation cohort.We refer to the data set obtained
using the second strategy as the first-blood-draw data set for the
derivation cohort.
Using data from the per-subject average data set for the deriva-
tion cohort, an ROC curve was calculated for the diagnosis of
WAS based on MPV and a separate ROC curve for the diagnosis
of WAS was calculated based on IPF and platelet count. Using
these curves and an à priori assumption that a 10% probability
of a patient having WAS would be a reasonable cut off for further
consideration of the diagnosis, a prediction rule was developed for
diagnosing WAS based on platelet and IPF values (the IPF/PLT
rule). We contrasted this rule with the classic rule of considering
WAS in any patient with an MPV less than the lower limit of
normal (the MPV rule).
In order to determine the diagnostic characteristics of the two
rules, a second set of data was obtained from BTRIS. All measures
of platelet counts, MPVs, and IPF reported at the hospital from
April 2, 2013 throughMarch 18, 2014 in subjects with a discharge
diagnosis of either WAS or ITP were collected. As for the deriva-
tion cohort, two data sets were created for the validation cohort, a
per-subject average data set and a first-blood-draw data set.
After obtaining the two data sets for the validation cohort, the
MPV rule and the IPF/PLT rule were each used separately to
determine a diagnosis ofWAS or ITP for each subject. These diag-
noses were then compared to the recorded discharge diagnoses to
determine sensitivity and specificity. Fisher’s exact test was used
to determine if each rule could significantly separate subjects with
WAS from subjects with a diagnosis of ITP. ROC curves based on
the per-subject average values in the validation cohort were then
calculated.
Descriptive statistics and diagnostic characteristics of the two
rules were calculated using Microsoft Excel for Macintosh 2011
version 14.3.8 or Microsoft Excel 2010 for Windows. Student’s
t-tests and Fisher’s exact tests were performed using calculators
available at www.graphpad.com. Logistic regressions, ROC curve
analysis, and the prediction rule were all calculated using SAS.
Results
Platelet Parameters for Subjects with WAS and
ITP
All data for the entire derivation cohort are presented in Table
S1 in Supplementary Material. There were 1,365 blood draws
for which a platelet count was available. In both subjects with
a diagnosis of ITP and subjects with WAS, as well as in both
groups together, the platelet counts were lower in CBCs that did
not report an MPV as compared with CBCs that did report an
MPV (Table 1). This difference was significant for subjects with a
diagnosis of ITP and for thewhole cohort, but only trended toward
significance for the smaller group of WAS subjects. These data
confirm that MPV is less likely to be reported when the platelet
count is lower.
Complete data, including a reported platelet count, MPV, and
IPF percentage, were available for 160 blood draws from 38 sub-
jects with a diagnosis of ITP and 27 blood draws from 18 subjects
TABLE 1 | Comparison of blood draws reporting or not reporting an MPV in
subjects with a diagnosis of ITP, in subjects with WAS, and in all subjects.
Number of
blood draws
% with
no MPV
Average platelet
counts
p
MPV
reported
No MPV
reported
MPV
reported
No MPV
reported
ITP 954 343 26 118,000 33,000 <0:0001
WAS 57 11 16 85,000 45,000 0:0961
Total 1;011 354 26 116,000 34,000 <0:0001
withWAS. These data are presented in Table S2 in Supplementary
Material. The per-subject average data set and the first-blood-
draw data set for the derivation cohort are presented in Table 2.
We used the first-blood-draw data set for the derivation cohort
to compare the platelet parameters of the subjects with WAS to
those of the subjects with a diagnosis of ITP. The IPF in subjects
with WAS was significantly lower than the IPF in subjects with a
diagnosis of ITP, although in both cases, the averages were within
the range of normal. The average MPV was significantly lower
in subjects with WAS than in subjects with a diagnosis of ITP,
being below the normal range in the former case and within the
normal range in the latter case. Platelet counts were also lower in
the subjects withWAS than in the subjects with a diagnosis of ITP,
although this difference was not statistically significant (Table 3).
Derivation of a Rule to Differentiate WAS and ITP
Because of the above-mentioned difficulties in obtaining MPV
values during the diagnostic workup of thrombocytopenic
patients, we attempted to develop amethod of separatingWAS and
ITP based only on platelet count and IPF. We performed logistic
regression ofWAS/ITP status on IPF and platelet values in the per-
subject average data set for the derivation cohort. The results of the
logistic regression can be visualized by examining a scatter plot of
average IPF vs. average platelet count in subjects withWAS or ITP
(Figure 1). Contour lines based on the logistic regression indicate
estimated probabilities of subjects to the left of the line having
WAS. ROC curves were generated for the diagnosis of WAS based
on MPV and for the diagnosis of WAS based on platelet count
and IPF (Figures 2A,B). We arbitrarily chose a 10% probability
of WAS as an appropriate level at which it would be reasonable
to consider further testing to rule out WAS in a boy with isolated
thrombocytopenia. Based on this decision, the logistic regression
indicated that a tentative diagnosis of WAS could be made, to be
followed by additional evaluation, when:
[(75 IPF) + Plt] < 500
where IPF is the IPF as a percentage and Plt is the platelet count
expressed as thousands of platelets per microliter.
Testing of the IPF/PLT Rule and the MPV Rule
with a Validation Cohort
To obtain unbiased estimates of sensitivity and specificity of the
IPF/PLT rule, we tested it against a subsequent independent data
set of platelet parameters for subjects with WAS and ITP. The
BTRIS systemwas again queried. All CBCs and IPFmeasurements
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TABLE 2 | Final data sets for the derivation cohort.
Subject Diagnosis Number of
blood draws
Average (SD) of all blood draws First-blood draw
Platelets/mcL MPV, fL IPF, % Platelets/mcL MPV IPF, %
1 Immune thrombocytopenic purpura 1 74;000 14:50 28:50
2 Immune thrombocytopenic purpura 1 91;000 10:60 3:80
3 Immune thrombocytopenic purpura 2 86;000 (16;000) 14:50 (0:28) 14:90 (1:27) 75;000 14:70 14:00
4 Wiskott–Aldrich syndrome 1 30;000 8:80 3:90
5 Immune thrombocytopenic purpura 1 419;000 9:60 1:50
7 Wiskott–Aldrich syndrome 1 204;000 9:60 1:40
8 Immune thrombocytopenic purpura 4 11;000 (2;000) 9:125 (1:08) 22:38 (6:28) 9;000 8:40 13:10
10 Immune thrombocytopenic purpura 1 198;000 13:10 10:10
11 Immune thrombocytopenic purpura 4 138;000 (28;000) 10:3 (0:41) 3:73 (0:67) 120;000 10:40 3:80
14 Wiskott–Aldrich syndrome 1 51;000 8:30 1:50
16 Immune thrombocytopenic purpura 1 39;000 13:40 12:90
17 Immune thrombocytopenic purpura 5 112;000 (14;000) 10:62 (0:43) 3:54 (1:45) 96;000 11:20 4:90
18 Wiskott–Aldrich syndrome 1 240;000 8:70 0:60
20 Immune thrombocytopenic purpura 10 280;000 (55;000) 11:78 (0:27) 5:3 (1:32) 340;000 12:00 3:80
21 Immune thrombocytopenic purpura 1 191;000 9:60 2:30
22 Immune thrombocytopenic purpura 5 135;000 (15;000) 11:12 (0:41) 4:96 (0:86) 160;000 11:20 3:70
23 Wiskott–Aldrich syndrome 3 111;000 (29;000) 9:60 (0:46) 1:47 (1:00) 129;000 9:20 0:70
24 Immune thrombocytopenic purpura 2 174;000 (16;000) 10:95 (0:28) 5:15 (1:27) 162;000 10:90 5:00
25 Wiskott–Aldrich syndrome 1 171;000 8:70 1:80
26 Wiskott–Aldrich syndrome 1 120;000 9:20 0:80
28 Wiskott–Aldrich syndrome 1 103;000 9:40 1:90
29 Immune thrombocytopenic purpura 1 386;000 10:00 1:60
31 Immune thrombocytopenic purpura 1 109;000 10:60 6:20
32 Immune thrombocytopenic purpura 2 59;000 (42;000) 10:80 (0:80) 4:85 (8:47) 29;000 11:60 7:10
33 Immune thrombocytopenic purpura 1 249;000 11:00 7:83
34 Wiskott–Aldrich syndrome 1 60;000 7:50 0:70
35 Immune thrombocytopenic purpura 1 72;000 10:20 5:90
37 Immune thrombocytopenic purpura 1 23;000 12:80 7:10
38 Wiskott–Aldrich syndrome 2 183;000 (12;000) 9:55 (0:42) 3:15 (1:23) 191;000 10:10 2:90
39 Immune thrombocytopenic purpura 35 200;000 (78;000) 10:29 (0:42) 5:46 (1:22) 329;000 9:50 4:40
40 Immune thrombocytopenic purpura 9 183;000 (22;000) 10:44 (0:20) 2:63 (0:78) 228;000 10:50 2:80
41 Wiskott–Aldrich syndrome 2 15;000 (6;000) 9:10 (0:14) 4:6 (5:90) 11;000 8:10 2:00
43 Immune thrombocytopenic purpura 1 170;000 9:60 3:00
44 Immune thrombocytopenic purpura 2 356;000 (139;000) 9:70 (0:00) 2:9 (1:13) 454;000 9:70 2:10
45 Immune thrombocytopenic purpura 3 199;000 (21;000) 10:40 (0:36) 2:77 (0:45) 223;000 10:00 2:80
47 Immune thrombocytopenic purpura 1 274;000 11:30 4:50
48 Immune thrombocytopenic purpura 1 130;000 11:90 5:80
49 Immune thrombocytopenic purpura 7 388;000 (19;000) 10:91 (0:31) 2:7 (0:51) 410;000 11:10 2:80
51 Immune thrombocytopenic purpura 3 227;000 (140;000) 11:27 (0:50) 5:57 (2:71) 370;000 11:20 4:70
52 Immune thrombocytopenic purpura 1 37;000 12:70 8:90
54 Immune thrombocytopenic purpura 7 84;000 (49;000) 11:17 (0:82) 5:24 (1:49) 27;000 10:70 10:30
55 Wiskott–Aldrich syndrome 1 38;000 8:80 1:50
56 Wiskott–Aldrich syndrome 1 57;000 9:00 4:60
57 Immune thrombocytopenic purpura 1 17;000 10:90 5:20
58 Immune thrombocytopenic purpura 3 32;000 (23;000) 9:93 (1:24) 7:90 (7:59) 31;000 11:60 9:70
59 Immune thrombocytopenic purpura 1 125;000 11:00 1:90
61 Immune thrombocytopenic purpura 3 24;000 (3;000) 11:47 (0:35) 6:83 (2:76) 26;000 11:80 4:20
62 Wiskott–Aldrich syndrome 1 47;000 8:40 1:00
63 Wiskott–Aldrich syndrome 3 25;000 (6;000) 8:00 (0:12) 3:18 (1:59) 23;000 9:20 1:90
64 Wiskott–Aldrich syndrome 1 35;000 8:40 3:80
65 Immune thrombocytopenic purpura 2 69;000 (20;000) 11:42 (0:86) 7:10 (2:83) 55;000 12:90 10:40
67 Immune thrombocytopenic purpura 1 216;000 9:90 3:30
68 Immune thrombocytopenic purpura 1 204;000 10:40 5:30
69 Immune thrombocytopenic purpura 27 94;000 (50;000) 11:60 (0:84) 6:01 (2:24) 46;000 10:50 4:90
70 Wiskott–Aldrich syndrome 1 34;000 8:20 1:70
71 Wiskott–Aldrich syndrome 4 115;000 (22;000) 8:83 (0:05) 1:33 (0:05) 94;000 8:80 1:40
In the per-subject average data set (left-hand columns), each value is an average of all measures of the indicated parameter for each subject. For subjects with more than one blood
draw, the SD of each average is given in parentheses. In the first-blood-draw data set (right-hand columns), the value of each parameter is from the first blood draw to report all three
parameters for each subject.
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TABLE 3 | Means (SDs) of platelet parameters from the first-blood-draw
data set for the derivation cohort.
Platelets/mcL MPV, fL IPF, %
ITP 149,00 (121,000) 11.2 (1.4) 6.6 (5.2)
WAS 92,000 (69,000) 8.8 (0.6) 2 (1.2)
Range of normal 161,000–347,000 9.4–12.4 0.9–11.2
p 0.07 <0.0001 <0.0001
FIGURE 1 | Probability contours for a predictor based on IPF and
platelet value. For each subject in the derivation cohort, all blood draws with
data on both platelet count and IPF were selected, and all values for the two
parameters were averaged for each subject and plotted. Red crosses
represent averages for ITP subjects and green x’s represent subjects with
WAS. Contour lines represent different probabilities of a subject having WAS.
from subjects with a discharge diagnosis of either ITP or WAS
that were drawn between April 2, 2013 and March 19, 2014 were
collected. This entire data set is presented in Table S3 in Supple-
mentaryMaterial. Blood drawswith complete data (platelet count,
MPV, and IPF) were selected, and are presented in Table S4 in
Supplementary Material. This data set included 28 blood draws
from 7 subjects with a diagnosis of ITP and 33 blood draws from
22 subjects with WAS. We used this data to create a per-subject
average data set and a first-blood-draw data set for the validation
cohort. These data sets are presented in Table 4.
The IPT/PLT rule and the MPV rule were each evaluated on
both the per-subject average data set and the first-blood-draw
data set for the validation cohort by comparing the predicted
diagnoses to the recorded discharge diagnoses. These results are
presented in Table 5. Using the per-subject average data set, both
rules significantly separated subjects withWAS from subjects with
a diagnosis of ITP, with p values of 0.0084 for the MPV rule and
0.0002 for the IPF/PLT rule. Using the first-blood-draw data set,
results were nearly identical, with p values of 0.0063 for the MPV
rule and 0.0002 for the IPF/PLT rule.
Sensitivities and specificities were calculated for each rule for
each data set. Using either data set, the MPV rule was perfectly
specific, with sensitivities of 0.59 for the per-subject average data
set and 0.64 for the first-blood-draw data set. Using the IPF/PLT
rule on either data set, sensitivity was 1 and specificity was 0.71.
ROC curves were again generated for the diagnosis of WAS
based on MPV and for the diagnosis of WAS based on platelet
count and IPF, using the per-subject average data set for the
validation cohort (Figures 3A,B). C-statistics for the two curves
were almost identical, showing that the IPF/PLT rule has overall
diagnostic accuracy similar to the MPV rule.
Discussion
WAS can often be separated from ITP on the basis of additional
findings, including eczema and frequent infections (24). Diag-
nosis of a boy with newly recognized thrombocytopenia should
take into account findings fromhistory, physical examination, and
laboratory evaluation. Nevertheless, the range of presentations
of WAS is quite broad. Only a minority of patients present with
the fullWiskott–Aldrich syndrome (27), whereas thrombocytope-
nia is almost always present (28). This makes the differential
diagnosis of WAS and ITP clinically relevant. Because the use
of MPV to distinguish WAS from ITP has a number of short-
comings, alternative strategies would be helpful. Our data show
that a rule constructed using the platelet count and IPF can have
greater sensitivity for the diagnosis of WAS than the traditional
rule using only the MPV, while maintaining overall diagnostic
accuracy.
Our data suggest that adding consideration of the IPF and
platelet count in the diagnostic algorithm for thrombocytopenia
in boys may allow for the detection of more patients with WAS
than would be detected using MPV. In order to justify an increase
in sensitivity at the expense of specificity, it is necessary to con-
sider the clinical utility of ruling in or ruling out WAS in a boy
newly found to have thrombocytopenia.
While the initial management of WAS with acute thrombo-
cytopenic bleeding is similar to the initial management of ITP
with acute thrombocytopenic bleeding, consisting of observa-
tion, IVIG, steroids, or some combination of these treatments,
the long-term management and prognoses of the two diseases
are quite different. For this reason, it might be appropriate to
favor a diagnostic strategy that sacrifices specificity for sensi-
tivity. Using the IPF/PLT rule for a theoretical population of
2,000,000 boys with thrombocytopenia (8 of whom would have
WAS and 80 of whom would have ITP), no WAS patients would
be missed, but 23 patients ITP would be initially diagnosed
with WAS. Using the traditional rule on the same cohort, no
patients with ITP would be felt to have WAS, but three diagnoses
of WAS would be missed. The clinical decision then becomes
whether it is preferable to initially misdiagnose eight boys with
ITP as having WAS or to misdiagnose one boy with WAS as
having ITP.
The above data show that subjects with Wiskott–Aldrich syn-
drome have a less robust thrombopoietic response to low platelet
counts than do subjects with a diagnosis of ITP. In addition to the
clinical utility of this observation, the data support the belief that
WAS is a thrombocytopenia of both increased thrombocytolysis
and decreased thrombopoiesis.
This study has a number of limitations. Foremost among these
is the retrospective nature of the study. These data were not
collected in order to evaluate the utility of using the IPF in addition
to the platelet count andMPV in the differential diagnosis ofWAS
and ITP, but rather were obtained in the course of routine or
investigational clinical care. Another limitation is that data were
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FIGURE 2 | ROC curve derived from (A) the MPV rule or (B) the IPF/PLT rule in the derivation cohort. Each open circle marks the sensitivity and specificity of
a given MPV cutoff. C-statistics appear in the lower right-hand corners of the graphs.
TABLE 4 | Final data sets for the validation cohort.
Subject Discharge diagnosis Number of
blood draws
Per-subject average
data set
First-blood-draw
data set
Average
platelets/mcL
Average
MPV, fL
Average
IPF, %
Platelets/
mcL
MPV,
fL
IPF, %
2 Wiskott–Aldrich syndrome 1 266;000 9:50 1:80 266;000 9:5 1:8
3 Wiskott–Aldrich syndrome 1 175;000 9:30 2:40 175;000 9:3 2:4
4 Wiskott–Aldrich syndrome 1 191;000 10:50 2:70 191;000 10:5 2:7
5 Wiskott–Aldrich syndrome 2 57;000 (16;000) 8:1 (0:14) 1:3 (0:85) 46;000 8:2 1:9
6 Wiskott–Aldrich syndrome 1 259;000 10:50 3:00 259;000 10:5 3
7 Immune thrombocytopenic purpura 1 124;000 10:00 5:50 124;000 10 5:5
9 Immune thrombocytopenic purpura 3 187;000 (17;000) 11:73 (0:06) 9:3 (0:26) 207;000 11:7 9:2
11 Wiskott–Aldrich syndrome 1 192;000 10:10 2:60 192;000 10:1 2:6
12 Wiskott–Aldrich syndrome 1 89;000 8:90 1:40 89;000 8:9 1:4
13 Wiskott–Aldrich syndrome 3 122;000 (16;000) 9:47 (0:23) 1:6 (0:44) 130;000 9:6 2:1
14 Wiskott–Aldrich syndrome 1 134;000 8:60 1:10 134;000 8:6 1:1
15 Wiskott–Aldrich syndrome 1 145;000 9:10 1:10 145;000 9:1 1:1
16 Wiskott–Aldrich syndrome 1 94;000 9:70 2:60 94;000 9:7 2:6
17 Immune thrombocytopenic purpura 1 423;000 9:90 1:70 423;000 9:9 1:7
18 Wiskott–Aldrich syndrome 1 224;000 10:20 2:50 224;000 10:2 2:5
19 Wiskott–Aldrich syndrome 1 20;000 7:80 2:30 20;000 7:8 2:3
20 Wiskott–Aldrich syndrome 1 214;000 10:10 2:50 214;000 10:1 2:5
21 Immune thrombocytopenic purpura 2 152;000 (50;000) 10:65 (0:07) 5:90 (2:26) 187;000 10:7 4:3
23 Wiskott–Aldrich syndrome 4 30;000 (10;000) 8:55 (0:59) 2:23 (0:61) 22;000 8 2
25 Immune thrombocytopenic purpura 1 152;000 10:10 2:60 152;000 10:1 2:6
26 Wiskott–Aldrich syndrome 1 33;000 8:80 4:40 33;000 8:8 4:4
27 Wiskott–Aldrich syndrome 2 155;000 (15;000) 8:70 (0:28) 0:95 (0:07) 166;000 8:5 1
28 Wiskott–Aldrich syndrome 3 21;000 (5;000) 9:57 (0:90) 5:37 (1:10) 25;000 9 5:3
30 Wiskott–Aldrich syndrome 1 40;000 8:10 3:00 40;000 8:1 3
31 Wiskott–Aldrich syndrome 2 40;000 (5;000) 8:75 (0:35) 1:30 (0:00) 37;000 9 1:3
32 Wiskott–Aldrich syndrome 2 41;000 (2;000) 8:6 (1:00) 1:00 (0:14) 39;000 8:9 1:1
33 Immune thrombocytopenic purpura 4 84;000 (10;000) 12:18 (0:73) 8:9 (0:90) 70;000 11:1 7:9
34 Immune thrombocytopenic purpura 16 87;000 (19;000) 10:21 (0:46) 3:79 (0:66) 81;000 10 4:1
35 Wiskott–Aldrich syndrome 1 104;000 9:20 0:70 104;000 9:2 0:7
In the per-subject average data set (left-hand columns), each value is an average of all measures of the indicated parameter for each subject. For subjects with more than one blood
draw, the SD of each average is given in parentheses. In the first-blood-draw data set (right-hand columns), the value of each parameter is from the first blood to report all three
parameters for each subject.
collected from a clinical database, rather than from a thorough
review of the subject charts.While this approach fulfills the ethical
imperative to maximize research subject privacy, the use of iso-
lated laboratory data removed from the clinical context is expected
to lead to some loss of data integrity. For example, the clinical
circumstances in which these values were obtained, including the
indication for blood draw, and perianalytical management with
platelet transfusion or other measures, were not determined. It is
possible, and in fact likely, that some of these blood draws were
obtained after platelet transfusion, and thus the numbers observed
may reflect the contribution of donor platelets to total platelet
count, MPV, and IPF. If this is the case, however, one would
expect such errors to be distributed similarly among subjects
with both ITP and WAS. The effect of this would be to blunt
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TABLE 5 | Discharge diagnoses and diagnoses determined by the MPV rule or by the IPF/PLT rule for the validation cohort.
Subject Discharge diagnosis Per-subject average data set First-blood-draw data set
Diagnosis by
MPV rule
Diagnosis by
IPF/Plt rule
Diagnosis by
MPV rule
Diagnosis by
IPF/Plt rule
2 Wiskott–Aldrich syndrome ITP WAS ITP WAS
3 Wiskott–Aldrich syndrome WAS WAS WAS WAS
4 Wiskott–Aldrich syndrome ITP WAS ITP WAS
5 Wiskott–Aldrich syndrome WAS WAS WAS WAS
6 Wiskott–Aldrich syndrome ITP WAS ITP WAS
7 Immune thrombocytopenic purpura ITP ITP ITP ITP
9 Immune thrombocytopenic purpura ITP ITP ITP ITP
11 Wiskott–Aldrich syndrome ITP WAS ITP WAS
12 Wiskott–Aldrich syndrome WAS WAS WAS WAS
13 Wiskott–Aldrich syndrome ITP WAS ITP WAS
14 Wiskott–Aldrich syndrome WAS WAS WAS WAS
15 Wiskott–Aldrich syndrome WAS WAS WAS WAS
16 Wiskott–Aldrich syndrome ITP WAS ITP WAS
17 Immune thrombocytopenic purpura ITP ITP ITP ITP
18 Wiskott–Aldrich syndrome ITP WAS ITP WAS
19 Wiskott–Aldrich syndrome WAS WAS WAS WAS
20 Wiskott–Aldrich syndrome ITP WAS ITP WAS
21 Immune thrombocytopenic purpura ITP ITP ITP ITP
23 Wiskott–Aldrich syndrome WAS WAS WAS WAS
25 Immune thrombocytopenic purpura ITP WAS ITP WAS
26 Wiskott–Aldrich syndrome WAS WAS WAS WAS
27 Wiskott–Aldrich syndrome WAS WAS WAS WAS
28 Wiskott–Aldrich syndrome ITP WAS WAS WAS
30 Wiskott–Aldrich syndrome WAS WAS WAS WAS
31 Wiskott–Aldrich syndrome WAS WAS WAS WAS
32 Wiskott–Aldrich syndrome WAS WAS WAS WAS
33 Immune thrombocytopenic purpura ITP ITP ITP ITP
34 Immune thrombocytopenic purpura ITP WAS ITP WAS
35 Wiskott–Aldrich syndrome WAS WAS WAS WAS
The left-hand columns use the per-subject average data set, and the right-hand columns use the first-blood-draw data set.
Assigned diagnoses in boldface differ from the discharge diagnoses.
FIGURE 3 | ROC curve derived from (A) the MPV rule or (B) the IPF/PLT rule in the validation cohort. Each open circle marks the sensitivity and specificity of
a given MPV cutoff. C-statistics appear in the lower right-hand corners of the graphs.
the observed differences, and so the persistence of statistically
significant differences betweenWAS and ITP subjects argues that
this source of error did not lead to important confounding.
As for any study of a rare disease, the small number of subjects
in the derivation cohort, and particularly in the validation cohort,
is an inherent weakness of this study. Furthermore, the proportion
of subjects with WAS in the two cohorts is not the same, likely
reflecting changes in research interests at the hospital from which
these data were derived. Gathering additional data in order to
expand the validation cohort might offset these differences, but
is not possible at this time.
A similar limitation in the data is the use of a unique population
enriched in subjects with WAS. Both the WAS subjects and the
ITP subjects seen at the single research facility from which data
were obtained may not well represent the general population
of patients with thrombocytopenia. This limitation is offset by
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having sufficient numbers of subjects with rare diseases to collect
enough data for meaningful analysis in a timely fashion.
The NIH Clinical Center is a referral-based clinical research
institution. As such, it is common that patients are seen after
initial diagnosis and treatment of the underlying disease. This
can explain why for some of the subjects analyzed in this study,
the platelet counts are higher than what one would expect for
patients newly presenting with ITP or WAS. Indeed, it is likely
that these patients were seen at the NIH Clinical Center after
their initial diagnosis of thrombocytopenia and, possibly, also
after treatment of low platelets had been initiated. Nevertheless,
we observed a significant difference in IPF between subjects with
ITP and subjects with WAS, which is a strength of the study and
indicates that the proposed rule is robust.
With respect to diagnostic attribution, only subjects with dis-
charge diagnoses of WAS or ITP were considered. Other poten-
tial subjects could have been identified by accepting admission
diagnoses or entries in problem lists as qualifying diagnoses.
This choice was not made because it was felt that discharge
diagnoses would be better substantiated than these other sources
of diagnosis. Because ITP is a diagnosis of exclusion, it is also
possible that some of the subjects identified as having ITP in
their discharge diagnoses did not, in fact, have the disease,
but had another cause of thrombocytopenia. Additional efforts
to substantiate the diagnosis of ITP would require individual
review of medical records, which we sought to avoid as noted
above.
Another limitation is the handling of the different number of
blood-draws for each subject. We used two different strategies to
address this, either looking at the average value of each parameter
for each subject or looking at the first-blood-draw with complete
data for each subject. Results of our analyses were similar using
either strategy. An alternativemight have been to use a generalized
linear mixed model in place of logistic regression, although this is
a more complex analysis and requires additional assumptions.
Not all hematology analyzers routinely report the IPF. This
may limit the generalizability of our study to some extent until
instrumentation updates are widespread.
Because patients with WAS can also genuinely develop ITP,
another concern would be the applicability of our rule to the
diagnosis of a patient with WAS and ITP. One might expect that
ITP in a WAS patient would not resolve the platelet production
defect of WAS. But, a sudden large decrease in platelets might
allow for a WAS patient to mount a thrombopoietic response
with a normal, rather than low, IPF. The moderate efficacy of
eltrombopag in WAS suggests that the megakaryocytes of WAS
patients respond somewhat to thrombopoietin receptor stimula-
tion, although this response may not be entirely normal. We were
unable to evaluate this clinical situation without chart review, and
the actual thrombopoietic response of patients withWAS to acute
ITP remains an important research question.
The present study has a number of strengths as well. The use of
electronically collected and archived data, as opposed to manual
chart review, may have increased the likelihood that all relevant
subjects were captured in the initial cohort. Refraining from chart
review also has the benefit of preventing arbitrary exclusion of
subjects based on data other than platelet count, MPV, IPF, and
discharge diagnosis. The fact that these data were collected retro-
spectively from actual clinical records, rather than prospectively as
planned research, argues for the applicability of the derived rules
to a “real-life” clinical setting. A second strength is the validation
of the proposed rule in a subsequent and independent validation
cohort.
The use of IPF in the differential diagnosis of WAS and ITP is
appealing for several practical reasons. The IPF can be reported
regardless of the platelet count, which is not the case for the
MPV. The parameter is typically available any time a CBC is run
on a hematology analyzer designed to capture it. Therefore, no
extra blood is required to run the test. As a numerical rather
than a qualitative evaluation, the use of IPF does not require
expertise in the evaluation of peripheral blood smears and thus
may allow a non-hematologist to suspect the diagnosis of WAS.
There is also intuitive appeal to using IPF in a manner analo-
gous to the role of the reticulocyte count in the evaluation of
anemia. An even simpler rule of thumb would be to consider
WAS only in thrombocytopenic patients whose IPF is not ele-
vated. No WAS subject in our study had a frankly elevated IPF,
whereas 4 of 38 subjects with a diagnosis of ITP had this finding.
While this rule is perfectly sensitive, the specificity is barely more
than 10%.
There are additional considerations in applying our data to the
clinical care of boyswith newly diagnosed thrombocytopenia. The
reticulated platelet percentage (an analyte similar to the IPF) is not
routinely used to diagnose ITP, and in a recent consensus docu-
ment, the reticulated platelet count was said to be of unproven or
uncertain benefit in the diagnosis of ITP (29). Our data do not
support using the IPF to confirm a diagnosis of ITP, but rather
using the IPF and platelet count to rule out the diagnosis of WAS
with enough confidence to avoid further testing. Should a child
be found to have a low IPF in the setting of newly recognized
thrombocytopenia, referral to an immunologist should be consid-
ered for the purpose of clinical correlationwith signs or symptoms
of immune dysregulation, such as eczema, infections, atopy, and
either a personal or family history of immunodeficiency.
While it is reasonable to assume that in a patient without
a pathologic cause of thrombocytopenia, low normal platelets
would be associated with an IPF in the upper part of the normal
range, we cannot rule out that situations may exist in which
healthy subjectswith no knownplatelet disorder could present low
normal platelet counts and low normal IPF, such that applying the
IPF/PLT rule would result in values consistent with the diagnosis
of Wiskott–Aldrich syndrome. Therefore, it seems advisable to
limit the application of the IPF/PLT rule to patients who have
thrombocytopenia, or who have a history of low platelet counts.
While this study focuses on the clinically important differential
diagnosis of ITP and WAS, the use of IPF may allow for separa-
tion of other inherited or acquired thrombocytopenias from ITP.
There is no à priori reason to suspect that this would not be pos-
sible, but data analogous to these data will need to be collected to
formally evaluate the use of IPF, or the IPF/PLT rule, in the differ-
ential diagnosis of other inherited or acquired thrombocytopenias
from ITP. Such a study has been done suggesting that the absolute
IPF value could be used to distinguish ITP fromacute lymphocytic
leukemia (ALL) and the IPF percentage to distinguish ITP from
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hypoproliferative thrombocytopenias including Fanconi anemia,
thrombocytopenia with absent radii, severe aplastic anemia, and
myelodysplastic syndrome (30).
In summary, the IPF is a convenient and readily available
platelet parameter. Its use can help to increase sensitivity of the
diagnosis of Wiskott–Aldrich syndrome, and potentially other
thrombocytopenias due to decreased production. This in turn
may spare children with these somewhat less common causes of
thrombocytopenia from ill-advised attempts at immunosuppres-
sion while allowing them to access appropriate, and potentially
definitive or life-saving, therapy in a timely manner. The data pre-
sented in this article are derived from an admittedly atypical but
nevertheless clinical cohort of subjects with thrombocytopenia. If
additional studies, including studies using prospectively collected
data, are consistent with the current study, the IPF/PLT rule or
another similar derivation can be validated as an appropriate first-
line study in the diagnosis of newly recognized thrombocytopenia.
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